{"url":"https://newsforagent.com/news/2026-11-03/biotalys-evoca-ng-dutch-trial-approval","markdown_url":"https://newsforagent.com/news/2026-11-03/biotalys-evoca-ng-dutch-trial-approval.md","title":"Biotalys Wins Dutch Approval for EVOCA NG Field Trials","headline":"Biotalys Gets Dutch Approval for Large-Scale EVOCA NG Trials on 350 Hectares","description":"Biotalys won Dutch approval to run EVOCA NG trials on up to 350 hectares of tomatoes, cucumbers and strawberries, ahead of a planned 2029 European launch.","section":"Regulation & Approvals","published_at":"2026-11-03T06:16:35+00:00","modified_at":"2026-11-03T06:16:35+00:00","author":"News Desk","key_takeaways":["The Dutch Board for the Authorisation of Plant Protection Products and Biocides approved large-scale EVOCA NG trials on up to 150 hectares of tomatoes, 150 hectares of cucumbers and 50 hectares of strawberries.","Biotalys plans European registration and launch of EVOCA NG in 2029, targeting a combined U.S. and E.U. market of around $1.1 billion.","Biotalys raised €12.05 million in a May 2026 private placement priced at €1.53 per share."],"companies":[{"name":"Biotalys","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000ei4/biotalys","website":"https://biotalys.com"}],"source":{"publisher":"GlobeNewswire","title":"Biotalys’ First Commercial Biofungicide EVOCA® NG Approved for Large-Scale Commercial Field Trials in the Netherlands","url":"https://www.globenewswire.com/news-release/2026/11/03/3393888/0/en/biotalys-first-commercial-biofungicide-evoca-ng-approved-for-large-scale-commercial-field-trials-in-the-netherlands.html"},"other_sources":[],"tags":["Regulation & Approvals","Biotalys"],"body_markdown":"Biotalys received approval from the Dutch Board for the Authorisation of Plant Protection Products and Biocides to run large-scale demonstration trials of its next-generation biofungicide candidate EVOCA NG on up to 150 hectares of tomatoes, 150 hectares of cucumbers and 50 hectares of strawberries. [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/03/3393888/0/en/biotalys-first-commercial-biofungicide-evoca-ng-approved-for-large-scale-commercial-field-trials-in-the-netherlands.html) published the announcement on November 3, 2026.\n\n## What the Dutch Trial Approval Covers\n\n[Biotalys](https://akta.pro/company-profiles/0000ei4/biotalys) is a Ghent-based AgTech company developing protein-based biocontrol crop protection products on its AGROBODY platform. The Dutch approval lets growers run commercial trials of EVOCA NG under real growing conditions, a first for the product, and allows harvested produce into the food chain.\n\nThe trials will test EVOCA NG against Botrytis and powdery mildew. Biotalys said the approval expands a demonstration program it ran in earlier years with EVOCA, its first-generation biocontrol.\n\n\"The approval of this demonstration program marks an important milestone for our company,\" said Carlo Boutton, Chief Executive Officer of Biotalys. He said the trials offer real-world validation of the company's first commercial product while it continues development and production optimisation.\n\nNoud Dings of Brookberries said the company applied EVOCA on 3.7 hectares of strawberries with great results, replacing a synthetic fungicide in a rotation program. Rob van Enckevort of De Peelkroon said EVOCA was used successfully against powdery mildew in strawberries for a second year in a row.\n\n## Biotalys Funding and Cost Cuts Behind the Program\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Biotalys closed a €12.05 million post-IPO private placement in May 2026, issuing 7,875,811 new shares at €1.53 per share, about 20.96% of its pre-transaction share base, to extend its cash runway and advance its pipeline. The same records show the company cut 30 jobs, roughly half its workforce, in February 2026 to save €20 million by the end of 2028, and held €8.0 million in cash at the end of 2025.\n\n## Earlier Steps Toward EVOCA Registration\n\nCalifornia granted state registration for EVOCA in September 2026, confirming the product met requirements for human health, environmental safety and efficacy, B2B Marketplace reported. In July 2026, the California Department of Pesticide Regulation began a 30-day public consultation on EVOCA following a positive Human Health Assessment, GlobeNewswire reported. Biotalys reported a normalised net loss of €7.2 million for the first half of 2026, down €0.9 million year on year, and appointed Carlo Boutton as CEO, GlobeNewswire reported in August 2026.\n\n## EVOCA NG Launch Timeline\n\nBiotalys plans European registration and launch of EVOCA NG in 2029, targeting a combined U.S. and E.U. market of around $1.1 billion. EVOCA NG shares its bioactive ingredient with EVOCA, which received EPA approval in the U.S. in December 2025 and state approval in Florida and California in 2026, with E.U. review ongoing. The company's [own announcement](https://biotalys.com) describes the trial program.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}